Afanix 40 mg (Afatinib)
Afatinib is basically Anti-Cancer Medicine and it is used for the first-line treatment of patients with metastatic non-small cell lung cancer.
|Product Name||: Afanix (Afatinib)|
|Generic Name||: Afatinib Dimaleate INN|
|Available Pack Size||: 30’s (3×10’s)|
|Available Strengths||: 40 mg|
Request A Call Back
What is Afanix 40mg?
Afanix 40mg is known to be one of the products used effectively for the treatment of non-small cell lung cancer. Afanix medicine 40mg with the active ingredient Afatinib acts on the target cancer cells, preventing its growth, along with making them self-destruct.
Basic information of Afanix 40mg
- Active ingredient: Afatinib.
- Categories: Anticancer drugs, protein kinase inhibitors.
- Trade name: Afanix.
- Preparation: Film-coated tablets.
- Packaging: Box of 3 blisters x 10 tablets.
- Origin: Beacon- Bangladesh.
- Each Afanix 40mg tablet contains:
- Afatinib as afatinib dimaleate - 40mg.
- Excipients 1 capsule.
- Afatinib is a powerful and selective, irreversible ErbB Family Blocker.
- Afatinib binds covalently and irreversibly blocks signals from all homozygotes and heterozygotes formed by ErbB family members EGFR (ErbB1), HER2 (ErbB2), ErbB3 and ErbB4.
- Absorption: Following oral administration of Afanix, the bioavailability of afatinib is observed approximately 2 to 5 hours after dosing.
- Distribution: The binding of afatinib to human plasma proteins is approximately 95%.
- Metabolism: Enzyme-catalyzed metabolic reactions play a negligible role for afatinib in vitro. Protein covalent products are the major cyclic metabolites of afatinib.
- Elimination: Following administration of 15 mg afatinib oral solution, 85.4% of the administered dose was recovered in feces and 4.3% in urine. The parent compound afatinib accounted for 88% of the recovered dose. Afatinib is eliminated with an effective half-life of approximately 37 hours.
- Giotrif 40mg
- Alecensa 150mg